The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma

Lenvatinib is appropriate for reducing the production of nitric oxide (NO) and facilitating as block angiogenesis. However, to our knowledge, there are no data that support the correlation between NO and clinical response in patients who received lenvatinib therapy for HCC.